These GLP-1 medications emulate the natural GLP-1 hormone found in the small intestine, influencing various aspects of metabolism.
GLP-1 medications, known as Glucagon-like peptide-1 receptor agonists, are a class of drugs employed in the management of type 2 diabetes
They stimulate the pancreas to release insulin, inhibit the secretion of glucagon, which elevates blood sugar, and delay digestion, promoting a prolonged feeling of fullness.
Common GLP-1 medications encompass Ozempic, Wegovy, Victoza, Byetta, Trulicity, and Mounjaro, some administered by injection while Rybelsus is taken orally. Presently, only Wegovy and Saxenda are FDA-approved as weight loss aids, but there’s a rising interest among non-diabetic individuals for off-label use.
Weight loss outcomes with GLP-1 medications can range from 4% to 17%, contingent on the individual’s health status and lifestyle changes like diet and exercise. A recent study scrutinized health insurance records of 16 million Americans between 2006 and 2020, focusing on prescriptions of semaglutide and liraglutide. The research revealed that those on GLP-1 medications agonists faced higher risks of gastrointestinal conditions compared to those on bupropion-naltrexone.
Dr. Rami Bailony, an obesity specialist, emphasized the importance of contextualizing relative risks, noting that while percentages may seem alarming, the actual number of affected individuals might be limited
Dr. Mir Ali, a bariatric surgeon, expressed that the results were not surprising given the known effects of GLP-1 medications agonists on the gastrointestinal tract.
Moving forward, controlled studies accounting for variables like smoking and gender differences are suggested to offer a more precise evaluation. Both experts emphasized the significance of informed decision-making in weight loss pursuits, prioritizing a shift towards healthier lifestyles regardless of the chosen intervention.